Ollin Biosciences’ VEGF/Ang2 bispecific antibody has shown superiority over Roche’s Vabysmo (faricimab) in a head-to-head trial in diabetic macular oedema (DME) or wet (neovascular) age-related macular degeneration (wAMD). In the Phase Ib JADE trial, OLN3... See more
Pulmocide has terminated a Phase III trial of its inhaled, respiratory drug after patients in the treatment group saw a higher mortality rate. The Phase III Opera-T trial (NCT05238116) was evaluating opelconazole in refractory invasive pulmonary aspergill... See more
One of the main challenges for medical device developers is ensuring clinical trials meet the expectations of all regulatory authorities in the regions where they wish to release. This will be a significant point of conversation at the 14th Annual Outsour... See more
GSK said that the drug met its primary endpoint, with more patients achieving functional cure with bepirovirsen plus standard of care compared to standard of care alone. Image credit: Magda Wygralak / Shutterstock.com GSK’s six-monthly triple-action inves... See more
GSK’s six-monthly triple-action investigational antisense oligonucleotide (ASO) candidate has demonstrated a clinically and statistically significant functional cure in chronic hepatitis B in two Phase III trials. The B-Well 1 (NCT05630807) and B-Well 2 (... See more
